Plain-English translation of NCT04437511 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
TRAILBLAZER-ALZ 2 is testing a medication called to see if it can help people in the early stages of Alzheimer's disease—when memory problems are just beginning. The medication works by targeting harmful proteins that build up in the brain. Researchers want to know if this treatment is safe and whether it can slow down cognitive decline.
Currently, there are limited options to slow the progression of early Alzheimer's disease. This trial is testing whether this medication could offer a new way to help people preserve memory and thinking skills during the earliest stages of the disease.
Participants will receive intravenous infusions (through a vein in your arm) of either the medication or placebo every 4 weeks for up to 72 weeks. You'll start with lower doses and gradually move to higher doses. During the study, you'll have regular visits for brain scans (PET and MRI), memory and thinking tests, and safety check-ups. Some participants may be invited to continue in an extended study period lasting another 78 weeks to monitor long-term effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States